Literature DB >> 20104280

Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.

Nicoletta Masera1, Luisa Tavecchia, Marietta Capra, Giovanni Cazzaniga, Chiara Vimercati, Lorena Pozzi, Andrea Biondi, Giuseppe Masera.   

Abstract

Entities:  

Keywords:  haemoglobin F; thalassaemia; thalidomide

Mesh：

Substances：

Year:  2010        PMID： 20104280      PMCID： PMC2809513          DOI： 10.2450/2009.0102-09

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  12 in total

1.  Interaction of heterocellular hereditary persistence of foetal haemoglobin with beta thalassaemia and sickle cell anaemia.

Authors:  W G Wood; D J Weatherall; J B Clegg
Journal:  Nature       Date:  1976-11-18       Impact factor: 49.962

Review 2.  Haemoglobin F modulation in childhood sickle cell disease.

Authors:  Sara Trompeter; Irene Roberts
Journal:  Br J Haematol       Date:  2008-11-20       Impact factor: 6.998

3.  Sodium butyrate inhibits histone deacetylation in cultured cells.

Authors:  E P Candido; R Reeves; J R Davie
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

4.  Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.

Authors:  Joseph DeSimone; Mabel Koshy; Louise Dorn; Donald Lavelle; Linda Bressler; Robert Molokie; Nasrin Talischy
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

5.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

6.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.

Authors:  T J Ley; J DeSimone; N P Anagnou; G H Keller; R K Humphries; P H Turner; N S Young; P Keller; A W Nienhuis
Journal:  N Engl J Med       Date:  1982-12-09       Impact factor: 91.245

7.  Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.

Authors:  S Fucharoen; N Siritanaratkul; P Winichagoon; J Chowthaworn; W Siriboon; W Muangsup; S Chaicharoen; N Poolsup; B Chindavijak; P Pootrakul; A Piankijagum; A N Schechter; G P Rodgers
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

8.  Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis.

Authors:  Wulin Aerbajinai; Jianqiong Zhu; Zhigang Gao; Kyung Chin; Griffin P Rodgers
Journal:  Blood       Date:  2007-07-09       Impact factor: 22.113

9.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Pharmacologic treatment of thalassemia intermedia with hydroxyurea.

Authors:  F M Hajjar; H A Pearson
Journal:  J Pediatr       Date:  1994-09       Impact factor: 4.406
View more
  11 in total

Review 1.  Foetal haemoglobin inducers and thalassaemia: novel achievements.

Authors:  Roberto Gambari
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

2.  Promising Response to Thalidomide in Symptomatic β-Thalassemia.

Authors:  Ahmed K Yassin
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-18       Impact factor: 0.900

3.  Alternative Strategies in Thalassemia: Focus on Thalidomide.

Authors:  R Naithani; P Jeyaraman; M Mahapatra
Journal:  Indian J Hematol Blood Transfus       Date:  2020-05-05       Impact factor: 0.900

4.  Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.

Authors:  Dinesh Bhurani; Jyotsna Kapoor; Neha Yadav; Vishvdeep Khushoo; Narendra Agrawal; Rayaz Ahmed; Jatinder Singh Arora; Pallavi Mehta
Journal:  Ann Hematol       Date:  2021-04-03       Impact factor: 3.673

Review 5.  Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.

Authors:  Filomena Longo; Andrea Piolatto; Giovanni Battista Ferrero; Antonio Piga
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 6.  Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders.

Authors:  Ali Dehghani Fard; Seyed Ahmad Hosseini; Mohammad Shahjahani; Fatemeh Salari; Kaveh Jaseb
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

7.  The role of epigenetics in the induction of fetal hemoglobin: a combination therapy approach.

Authors:  Mohammad Ahmadvand; Mehrdad Noruzinia; Ali Dehghani Fard; Mostafa Montazer Zohour; Mohammad Amin Tabatabaiefar; Masoud Soleimani; Saeid Kaviani; Saeid Abroun; Sahar Beiranvand; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

Review 8.  Erythropoiesis: insights into pathophysiology and treatments in 2017.

Authors:  Andrea Zivot; Jeffrey M Lipton; Anupama Narla; Lionel Blanc
Journal:  Mol Med       Date:  2018-03-23       Impact factor: 6.354

9.  Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.

Authors:  Jiang-Ming Chen; Wei-Jian Zhu; Jie Liu; Gui-Zhen Wang; Xiao-Qin Chen; Yun Tan; Wei-Wei Xu; Li-Wei Qu; Jin-Yan Li; Huan-Ju Yang; Lan Huang; Ning Cai; Wei-Da Wang; Ken Huang; Jian-Quan Xu; Guo-Hui Li; Sheng He; Tian-Ying Luo; Yi Huang; Song-Hua Liu; Wen-Qiang Wu; Qi-Yang Lu; Mei-Guang Zhou; Shu-Ying Chen; Rong-Lan Li; Mei-Ling Hu; Ying Huang; Jin-Hua Wei; Jun-Min Li; Sai-Juan Chen; Guang-Biao Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-11-18

10.  Thalidomide for Patients with β-Thalassemia: A Multicenter Experience.

Authors:  Kun Yang; Yi Wu; Yali Zhou; Binbin Long; Qian Lu; Tianhong Zhou; Li Wang; Zhili Geng; Xiaolin Yin
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-05-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.